The etiology of pancreatic cancer remains largely unknown. Here, we report the results of a meta-analysis of three genome-wide association studies (GWASs) comprising 2,039 pancreatic cancer cases and 32,592 controls, the largest sample size in the Japanese population. We identified 3 (13q12.2, 13q22.1, and 16p12.3) genome-wide significant loci (P<5.0×10 -8 ) and 4 suggestive loci (P<1.0×10 -6 ) for pancreatic cancer. Of these risk loci, 16p12.3 is novel; the lead SNP maps to rs78193826 (odds ratio (OR)=1.46, 95% CI=1.29-1.66, P=4.28×10 -9 ), an Asian-specific, nonsynonymous glycoprotein 2 (GP2) gene variant predicted to be highly deleterious. Additionally, the gene-based GWAS identified a novel 5 gene, KRT8, which is linked to exocrine pancreatic and liver diseases. The identified GP2 gene variants were pleiotropic for multiple traits, including type 2 diabetes, hemoglobin A1c (HbA1c) levels, and pancreatic cancer. Mendelian randomization analyses corroborated causality between HbA1c and pancreatic cancer. These findings suggest that GP2 gene variants are associated with pancreatic cancer susceptibility in the Japanese population, prompting further functional characterization of this locus.
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GWAS to populations of non-European ancestry because of differences in minor allele frequencies (MAFs) and patterns of linkage disequilibrium (LD) across diverse populations 7 .
In fact, previous GWASs focusing exclusively on populations of Eastern Asian ancestry led to the identification of new susceptibility loci for breast and colorectal cancers 8, 9. The majority of the risk loci for pancreatic cancer were discovered in the PanScan GWASs, which included populations of European ancestry. Only two GWASs have been conducted in East Asian populations: one in China 10 and one in Japan 11 . A total of 8 risk loci (5 genomewide significant loci and 3 loci with suggestive evidence of association) have been identified for pancreatic cancer, but these loci were not replicated in a previous study using samples from European populations 12 . Therefore, the role of common susceptibility loci in East Asian populations remains uncertain and needs further exploration. To detect additional susceptibility loci for pancreatic cancer, we conducted another GWAS in the Japanese population and then performed a meta-analysis combining all published and unpublished GWAS data in Japan.
Results
After imputation and quality control, we performed a meta-analysis of three Japanese GWASs comprising 2,039 cases and 32,592 controls as well as 7,914,378 SNPs (Supplementary Table 1 and Table 2 ). Genomic control adjustment was not applied because there was little evidence of genomic inflation (lambda=1.03, Supplementary Figure   1 ). We observed genome-wide significant (P<5.0×10 -8 ) association signals at 3 loci (13q12.2, 13q22.1, and 16p12.3) ( Figure 1 and Table 1) , for which the genes nearest the lead SNP were PLUT (PDX1-AS1), KLF5, and GP2, respectively. In addition, 4 loci (1p13.2 (WNT2B), 2p12 (CTNNA2), 3p12.3 (ROBO2), and 9q34.2 (ABO)) showed suggestive evidence of association (P<1.0×10 -6 ) (Figure 1 and Table 1 ). The association results of each study are shown in Supplementary Table 3 . Among these risk loci, 16p12.3 is a novel locus, with genome-wide significant associations observed for 10 SNPs in this region (rs78193826, rs117267808, rs73541251, rs4609857, rs4544248, rs4632135, rs4420538, rs73541271, rs4383154, and rs4383153) (Supplementary Table 4 ). The ORs for these variants ranged from 1.43 to 1.47, indicating stronger associations in this region than the associations indicated by the odds ratios (ORs) for variants identified in previously published GWASs.
The lead SNP maps to rs78193826, a nonsynonymous variant of the GP2 (Figure 2 ) gene.
The risk increased by 46% per copy of the minor T allele (OR=1.46, 95% CI=1.29-1.66, P=4.28×10 -9 ) (Table 1). Regional association plots for the other loci are shown in Supplementary Figure 2 . According to the 1000 Genomes Project Phase 3 database, rs78193826 is polymorphic, with a MAF ranging from 3.9% to 6.6% in Asian populations, compared with the much lower MAF (<0.1%) in other human populations ( Supplementary   Table 4 ). LD maps of these 10 SNPs at 16p12.3 are shown in Supplementary Figure 3 .
Complete LD between 9 of these SNPs (all except rs4420538) was observed in the Japanese population. Among the 10 SNPs in this region, only rs4383153 had available association summary statistics in the previous PanScan publications 2, 13 , but this SNP was not significantly associated with pancreatic cancer risk (Supplementary Table 5 ). The functional annotation results for the 10 SNPs at 16p12.3 are shown in Supplementary Table 4 . The lead SNP rs78193826 was classified as "damaging" according to the Sifting Intolerant from Tolerant (SIFT) algorithm and as "possibly damaging" by Polymorphism Phenotyping v2 (PolyPhen-2). Moreover, the estimated combined annotation-dependent depletion (CADD) score was 20.3. For replication, we selected 4 SNPs (rs78193826, rs73541251, rs117267808, rs4632135) that met either of the following criteria: 1) exonic SNP or 2) intronic SNP with a score of 3 or less according to the Regulome DB database.
Analysis of another independent replication cohort comprising 507 cases and 879 controls showed that rs4632135 (an intronic variant) was nominally significantly associated with pancreatic cancer risk (P<0.05), whereas the other 3 SNPs did not show nominal significance (Table 2) . However, the direction and magnitude of the effects for all 4 SNPs was consistent with those observed in the GWAS meta-analysis. Furthermore, the combined analysis of the three GWASs and the replication dataset yielded lower P values than those of the GWAS meta-analysis for each SNP ( Table 2 ), suggesting that the novel risk locus at 16p12.3 discovered in our GWAS meta-analysis was unlikely to be false positive.
We also examined the previously published pancreatic cancer risk loci from PanScan 14 , noting that 11 of those 19 SNPs were nominally statistically significant (rs13303010 at 1p36.33, rs3790844 at 1q32.1, rs9854771 at 3q28, rs2736098 at 5p15.33, rs401681 at 5p15.33, rs10094872 at 8q24.21, rs505922 at 9q34.2, rs9581943 at 13q12.2, rs7214041 at 17q24.3, and rs16986825 at 22q12.1) or genome-wide significant (rs9543325 at 13q22.1) in our GWAS meta-analysis (Supplementary Table 6 ). Notably, we confirmed the nominally significant association (P<3.84×10 -5 ) between rs505922 of the ABO locus and pancreatic cancer risk.
Epidemiological studies have consistently shown that longstanding T2D is associated with an increased risk of pancreatic cancer 15 . Recently, 88 genetic variants, including both novel and established variants, were reported in a GWAS meta-analysis of T2D in the Japanese population 16 . We found that the top 3 SNPs at 16p12.3 (rs78193826, rs117267808, and rs73541251) were also genome-wide significantly associated with the risk of T2D in the latest GWAS comprising 191,764 Japanese subjects ( Supplementary Table 7 ). In addition, these 3
SNPs were nominally significantly associated with hemoglobin A1c (HbA1c) (P<1×10 -4 ) and blood glucose levels (P<0.01), which were included in another GWAS of quantitative traits in 42,790 and 93,146 Japanese subjects, respectively 17 . In addition to the GP2 SNPs, 4 of the 82 T2D-associated SNPs (rs838720 at 2q37.1 (DGKD), rs2233580 at 7q32.1 (PAX4), rs2290203 at 15q26.1 (PRC1-AS1), and rs663129 at 18q21.32 (MC4R)) were nominally significant in our GWAS meta-analysis (Supplementary Table 8 ). In addition, one of the 25 HbA1cassociated SNPs (rs4728092 at 7q32.1 (SND1)) was nominally significant in our GWAS meta-analysis (Supplementary Table 9 ).
To examine whether the associations of T2D and T2D-related quantitative traits with pancreatic cancer are consistent with a causal effect, we performed a Mendelian randomization (MR) analysis with the inverse variance-weighted (IVW) and MR-Egger methods. No significant associations were observed between SNP-modulated T2D and pancreatic cancer based on the IVW method (Figure 3a) . Instead, genetically increased HbA1c levels appeared to be causally related to an increased risk of pancreatic cancer, on the basis of the significant results with both the IVW and MR-Egger methods (Figure 3b and Supplementary Figure 4b) .
To complement the SNP-based GWAS, we performed a gene-based GWAS using MAGMA 18 (Supplementary Figure 5) . We confirmed the significant associations for GP2 and WNT2B identified by the SNP-based GWAS. Notably, a novel significant association (Bonferroni-corrected P < 2.84 × 10 −6 ) for the gene KRT8 was observed ( Supplementary   Table 10 and Supplementary Figures 5 and 6 ), and this association was further replicated in the PanScan 1 and PanScan 2 datasets (P=0.024) 13 .
Discussion
The role of inherited common genetic variations in pancreatic cancer susceptibility remains incompletely understood. We identified and replicated a novel risk locus at 16p12.3 for pancreatic cancer through combining three GWAS datasets in the Japanese population.
Furthermore, we provided evidence that the identification of this new locus can be attributed to the observed differences in the MAF of the lead SNP (rs78193826) at 16p12.3 and the LD structure in this region across ethnic populations.
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Little overlap has been observed when risk loci reported from previous Chinese or Japanese GWASs are compared with those reported in the PanScan GWASs 2 . By including more than twice the number of cases than were included in previous Japanese or Chinese GWASs as well as imputed SNP data, we replicated the majority of the significant risk loci discovered in the PanScan GWASs ( Supplementary Table 6 ). Moreover, for most variants, the direction and magnitude of the effects in our GWAS meta-analysis of Japanese subjects were consistent with those in populations of European ancestry. These findings suggested that GWASidentified causal variants at many loci are shared across ancestral groups and that the lack of replication may be due to an insufficient sample size in previous Chinese or Japanese GWASs.
Several lines of evidence indicate that rs78193826 is most likely a causal variant at 16p12.3, which harbors the GP2 gene. First, this variant is nonsynonymous; the nucleotide mutation from C to T causes an amino acid change from valine to methionine, which could affect protein structure and function. Second, functional annotations in several databases consistently indicate that this variant is highly pathogenic. Third, the observed differences in the MAF of rs78193826 as well as the LD structure across different ethnic populations provide indirect evidence supporting its role as a causal variant in the Japanese population.
The frequency of the minor T allele of rs78193826 is 0.1% in populations of European ancestry but 7% in the Japanese population. Given this apparent difference in the MAF, rs78193826 could not have been identified in the PanScan GWASs, although the PanScan GWASs included a much larger sample size than our GWAS. Of the 10 SNPs in this region, only rs4383153 has association summary statistics available in PanScan publications; however, no significant associations were observed between this SNP and pancreatic cancer risk ( Supplementary Table 5 ). While complete LD between rs4383153 and rs78193826 was evident in the Japanese population, no LD data were available for these two SNPs in the European ancestry populations (1000 Genomes Project Phase 3 CEU). As the frequency of the minor T allele of rs78193826 ranges from 3.9% to 6.6% in other Asian populations, rs78193826 is likely to be a causal variant for pancreatic cancer that is specific to Asian populations. However, further transethnicity replicability and fine mapping are necessary to establish the causal role of this variant.
Genetic variations in the GP2 gene have been linked to several phenotypes in addition to pancreatic cancer. The SNP rs12597579, located in the upstream region of the GP2 gene, has been associated with body mass index (BMI) in a GWAS including East Asians 19 . However, rs12597579 was not in LD with rs78193826 (r 2 =0.003, calculated from Japanese samples in the 1000 Genomes Project Phase 3), suggesting that rs12597579 may have functions different from those of rs78193826. Coincidently, the lead variant (rs117267808) in the GP2 gene identified in the latest GWAS meta-analysis of T2D in the Japanese population is the same variant that we identified in our GWAS meta-analysis of pancreatic cancer (Supplementary Table 7 ). Of the 82 T2D-related SNPs, 5 showed significant associations (P<0.05) with pancreatic cancer, suggesting that pancreatic cancer and T2D may share specific genetic susceptibility factors. Furthermore, the risk alleles of rs78193826 and rs117267808 were identical for pancreatic cancer and T2D. Together, these findings indicate that GP2 variants may exert pleiotropic effects on multiple traits.
The newly identified lead SNP (rs78193826) encodes the GP2 protein, which is present on the inner surface of zymogen granules in pancreatic acinar cells 20 Figure 8 ) 23 . The functional consequence of the lead SNP can be, in part, inferred from its location in the GP2 gene: the ZP domain. In addition to GP2, an increasing number of proteins, such as uromodulin 24 and the transforming growth factor (TGF)-β receptor III 25 , have been found to contain a ZP domain, the functions of which involve extracellular matrix formation and polymerization 26 . In particular, uromodulin, the most abundant protein secreted by the kidney, shares 55% amino acid sequence identity with GP2 in the ZP-C subdomain 24 .
Pathogenic mutations in the UMOD gene have been shown to affect the structure and polymerization of uromodulin, resulting in kidney disease 24 . Given the similarity in the amino acid sequence as well as the expected functionality between these two proteins, genetic However, accumulating evidence has demonstrated the effects of GP2 on the innate immune response 28, 29 . The GP2 is also expressed in the membranous (M) cells of the intestinal epithelium in humans and mice, where it acts as an uptake receptor for a subset of commensal and pathogenic bacteria 30 . For example, GP2 and its closest homolog, uromodulin, have been shown to bind to Escherichia coli (E. coli) that express type 1 fimbriae 31 . In particular, uromodulin null mice showed increased sensitivity to urinary tract infections 24 . These findings suggest that GP2 may also play a role in host defense in the pancreas, given that proteobacteria have been detected in pancreatic ductal adenocarcinoma samples as well as in the normal human pancreas 32 .
Previous epidemiological studies have suggested that HbA1c levels, even in nondiabetic ranges, or changes in HbA1c levels in new-onset T2D are associated with pancreatic cancer risk 33, 34 . Our MR analysis provided corroborating evidence that genetically increased HbA1c levels may be causally associated with pancreatic cancer risk. This result was also partially consistent with a previous MR analysis, in which T2D was not causally implicated but BMI and fasting insulin were causally associated with pancreatic cancer 35 . Because known HbA1crelated genetic variants explain little of the variance in HbA1c levels, further studies are needed to strengthen the causal inference by incorporating more variants. The null findings on the causal role for T2D may reflect the phenotypic and genetic heterogeneity of T2D, but T2D may also be both a cause and consequence of pancreatic cancer 35 .
Three genome-wide significant genes (GP2, WNT2B, and KRT8) emerged in the gene-based GWAS. Among these genes, WNT2B was reported in the previous PanScan GWAS as a novel gene at 1p13.1 with suggestive evidence of association 6 , and KRT8 is a novel finding. KRT8
belongs to a group of intermediate-filament cytoskeletal proteins involved in maintaining epithelial structural integrity 36 . KRT8 is expressed in both ductal and acinar single-layer epithelia, and mutations in the KRT8 gene have been linked to exocrine pancreatic disorders and liver disease 37, 38 .
In conclusion, our GWAS meta-analysis identified a novel risk locus at chromosome 16p12.3, which harbors the GP2 gene, for pancreatic cancer in the Japanese population.
Further fine mapping and functional characterization are required to elucidate the effects of common GP2 gene variants on pancreatic cancer susceptibility. Moreover, our findings highlight genetic susceptibility factors shared between T2D and pancreatic cancer.
Methods

Study samples.
We performed a GWAS meta-analysis based on three Japanese studies: the Japan Pancreatic Cancer Research (JaPAN) consortium GWAS, the National Cancer Center (NCC) GWAS, and the BioBank Japan (BBJ) GWAS. An overview of the characteristics of the study populations is provided in Supplementary Table 1 . Information on the studyspecific genotyping, imputation, and analysis tools is provided in Supplementary Table 2 .
All studies were imputed based on the 1000 Genomes Project reference panel (Phase 3).
JaPAN consortium GWAS. Participants in this GWAS were drawn from the JaPAN consortium 39 . Two case-control datasets were combined, resulting in a total of 945 pancreatic NCC GWAS. The case and control samples were derived from a previous pancreatic cancer GWAS 11 . The cases were 677 patients diagnosed with invasive pancreatic ductal adenocarcinoma at the NCC Hospital, Tokyo, Japan. The control population consisted of 677 Japanese volunteers who participated in a health checkup program in Tokyo. After preimputation quality control, 674 cases and 674 controls remained for the subsequent analysis ( Supplementary Table 2 ). This project was approved by the ethics committee of the NCC.
Quality control after genotype imputation
After genotype imputation, quality control was applied to each study. SNPs with an imputation quality of r 2 < 0.5 or a MAF of <0.01 were excluded. SNPs that passed quality control in at least two cohorts were included in the meta-analysis.
Association analysis for SNPs and pancreatic cancer
The association of pancreatic cancer with SNP allele dose was tested using logistic 1 6 regression analysis with adjustment for the top 2 principal components. Other known covariates, such as age, sex, and cigarette smoking, were not included in the analysis because the inclusion of covariates has been shown to substantially reduce the power for the identification of disease-associated variants when the disease prevalence is less than 2% 41 .
The effect sizes and standard errors were used in the subsequent meta-analysis.
Meta-analysis
We performed a meta-analysis of three pancreatic cancer GWASs (JaPAN, BBJ and NCC).
The association results for each SNP across the studies were combined with METAL software in a fixed effects inverse variance-weighted meta-analysis. Heterogeneity in allelic effects was assessed using the I 2 index. The meta-analysis included 7,914,378 SNPs with genotype data available from at least two cohorts. A P value threshold of 5 × 10 -8 was used to determine genome-wide significance. We assessed the inflation of test statistics using the genomic control lambda.
Replication analysis
The replication cohort comprised 507 cases and 879 controls who were recruited under the same framework as the multi-institutional case-control study of the JaPAN consortium 
Functional annotations
To prioritize the associated SNPs at the novel loci, we adopted a series of bioinformatic approaches to collate functional annotations. We first used ANNOVAR 42 to obtain an aggregate set of functional annotations-including the gene location and the impact of the amino acid substitution based on prediction tools such as SIFT, PolyPhen-2, and CADD-for SNPs with a P value of <5 × 10 -8 for pancreatic cancer. We also explored potential effects on gene regulation by annotating these SNPs using the RegulomeDB database 43 .
MR analysis
We performed MR analyses using independent, genome-wide significant T2D-associated or HbA1c-associated SNPs, which were available from two published GWAS meta-analyses in Japanese subjects, as instrumental variables 16, 17 . For the two-sample MR analysis of T2D and pancreatic cancer, we did not exclude the overlapping samples (15.5% found only in the controls) because retaining these samples was unlikely to introduce substantial bias 44 . A total of 106 pancreatic cancer cases were excluded in the HbA1c GWAS, and the effect sizes for the HbA1c-associated SNPs were reestimated. After the exclusion of 6 SNPs on the X chromosome (5 SNPs for T2D and 1 SNP for HbA1c) and an SNP for T2D (rs35678078) without genotype data, the summary data for 82 T2D-related SNPs and 25 HbA1c-related SNPs and the associations of these SNPs with pancreatic cancer risk were analyzed using IVW and MR-Egger regression methods. MR analysis was performed with the MendelianRandomization package 45 .
Gene-based analysis
SNP-based P values were combined into gene-based P values using MAGMA software version 1.06 18 . SNP summary statistics (P values) from the meta-analysis were used as input for MAGMA. In gene-based association tests, LD between SNPs was accounted for, and the P value threshold for genome-wide significant associations was set at 2.84×10 −6 . The 1000
Genomes reference panel (Phase 3, East Asian) was used to control for LD. We did not include any upstream/downstream regions around the genes in this analysis; only variants located between the first exon and the last exon of a gene were used to calculate the gene- HbA1c-associated SNPs. 
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